Ella versus Simoa Serum Neurofilament Assessment to Monitor Treatment Response in Highly Active Multiple Sclerosis Patients
The measurement of serum neurofilament light chain (sNfL) is of growing importance in the field of neurology. In the management of multiple sclerosis, it can serve as a useful marker to assess disease activity and treatment response. This paper compares two available methods, namely the Single Molec...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-10-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/23/20/12361 |
| _version_ | 1797440860403531776 |
|---|---|
| author | Martin Nötzel Luise Ina Werder Tjalf Ziemssen Katja Akgün |
| author_facet | Martin Nötzel Luise Ina Werder Tjalf Ziemssen Katja Akgün |
| author_sort | Martin Nötzel |
| collection | DOAJ |
| description | The measurement of serum neurofilament light chain (sNfL) is of growing importance in the field of neurology. In the management of multiple sclerosis, it can serve as a useful marker to assess disease activity and treatment response. This paper compares two available methods, namely the Single Molecule Array (Simoa) and the Ella microfluid platform, to measure longitudinal sNfL levels of 42 highly active multiple sclerosis patients treated with alemtuzumab over a period of 36 months. In order to assess the methods agreement, Bland–Altman plots and Passing–Bablok regression were analyzed. Here, we show that despite the fact that Ella measures around 24% higher values than Simoa, both are equally suitable for longitudinal sNfL monitoring. |
| first_indexed | 2024-03-09T12:14:31Z |
| format | Article |
| id | doaj.art-18399e033e3c43bca62e657cafe53f94 |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-09T12:14:31Z |
| publishDate | 2022-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-18399e033e3c43bca62e657cafe53f942023-11-30T22:47:26ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672022-10-0123201236110.3390/ijms232012361Ella versus Simoa Serum Neurofilament Assessment to Monitor Treatment Response in Highly Active Multiple Sclerosis PatientsMartin Nötzel0Luise Ina Werder1Tjalf Ziemssen2Katja Akgün3Department of Neurology, Technische Universität Dresden, 01307 Dresden, GermanyDepartment of Neurology, Technische Universität Dresden, 01307 Dresden, GermanyDepartment of Neurology, Technische Universität Dresden, 01307 Dresden, GermanyDepartment of Neurology, Technische Universität Dresden, 01307 Dresden, GermanyThe measurement of serum neurofilament light chain (sNfL) is of growing importance in the field of neurology. In the management of multiple sclerosis, it can serve as a useful marker to assess disease activity and treatment response. This paper compares two available methods, namely the Single Molecule Array (Simoa) and the Ella microfluid platform, to measure longitudinal sNfL levels of 42 highly active multiple sclerosis patients treated with alemtuzumab over a period of 36 months. In order to assess the methods agreement, Bland–Altman plots and Passing–Bablok regression were analyzed. Here, we show that despite the fact that Ella measures around 24% higher values than Simoa, both are equally suitable for longitudinal sNfL monitoring.https://www.mdpi.com/1422-0067/23/20/12361neurofilamentEllaSimoamethod comparisonalemtuzumab |
| spellingShingle | Martin Nötzel Luise Ina Werder Tjalf Ziemssen Katja Akgün Ella versus Simoa Serum Neurofilament Assessment to Monitor Treatment Response in Highly Active Multiple Sclerosis Patients International Journal of Molecular Sciences neurofilament Ella Simoa method comparison alemtuzumab |
| title | Ella versus Simoa Serum Neurofilament Assessment to Monitor Treatment Response in Highly Active Multiple Sclerosis Patients |
| title_full | Ella versus Simoa Serum Neurofilament Assessment to Monitor Treatment Response in Highly Active Multiple Sclerosis Patients |
| title_fullStr | Ella versus Simoa Serum Neurofilament Assessment to Monitor Treatment Response in Highly Active Multiple Sclerosis Patients |
| title_full_unstemmed | Ella versus Simoa Serum Neurofilament Assessment to Monitor Treatment Response in Highly Active Multiple Sclerosis Patients |
| title_short | Ella versus Simoa Serum Neurofilament Assessment to Monitor Treatment Response in Highly Active Multiple Sclerosis Patients |
| title_sort | ella versus simoa serum neurofilament assessment to monitor treatment response in highly active multiple sclerosis patients |
| topic | neurofilament Ella Simoa method comparison alemtuzumab |
| url | https://www.mdpi.com/1422-0067/23/20/12361 |
| work_keys_str_mv | AT martinnotzel ellaversussimoaserumneurofilamentassessmenttomonitortreatmentresponseinhighlyactivemultiplesclerosispatients AT luiseinawerder ellaversussimoaserumneurofilamentassessmenttomonitortreatmentresponseinhighlyactivemultiplesclerosispatients AT tjalfziemssen ellaversussimoaserumneurofilamentassessmenttomonitortreatmentresponseinhighlyactivemultiplesclerosispatients AT katjaakgun ellaversussimoaserumneurofilamentassessmenttomonitortreatmentresponseinhighlyactivemultiplesclerosispatients |